| 1 |
Phase 1 clinical development of PG-102, a next-generation GLP-1/GLP-2 dual agonist for treating obesity and diabetes |
| rProtein |
Obesity, Type 2 Diabetes |
GLP-1, GLP-2 수용체 |
Phase 1 |
ProGen Co., Ltd. |
RS-2024-00335179 |
|
| 2 |
A First-in-Class Treatment for Non-alcoholic Steatohepatitis |
| Small molecules |
NASH |
HTR2A |
Phase 1 |
JD BIOSCIENCE INC. |
RS-2023-00218035 |
|
| 3 |
JP-2266: Novel SGLT1/2 dual inhibitor for the treatment of diabetes mellitus |
| Small molecules |
Diabetes |
SGLT1/2 |
Phase 1 |
Jeil Pharmaceutical Co., Ltd. |
HN21C0675 |
|